Systematic Review

Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis

Chun-Kai Liao 1, Ya-Ting Kuo 1, Yueh-Chen Lin 1, Yih-Jong Chern 1, Yu-Jen Hsu 1, Yen-Lin Yu 2, Jy-Ming Chiang 1,2,3, Pao-Shiu Hsieh 1,2,3, Chien-Yuh Yeh 1,2 and Jeng-Fu You 1,2,*

1 Division of Colon and Rectal Surgery, Department of Surgery, Chang Gung Memorial Hospital, Linkou, No. 5, Fuxing St., Guishan Dist., Taoyuan 333423, Taiwan; mr9023@cgmh.org.tw (C.-K.L.);
kyu52623@cgmh.org.tw (Y.-T.K.);
lv8295@cgmh.org.tw (Y.-C.L.);
Chiang, J.-M.; Hsieh, P.-S.; Yeh, C.-Y.; You, J.-F. Neoadjuvant Short-Course Radiotherapy Followed by Consolidation Chemotherapy before Surgery for Treating Locally Advanced Rectal Cancer: A Systematic Review and Meta-Analysis. Curr. Oncol. 2022, 29, 3708–3727. https://doi.org/10.3390/curroncol29050297

Received: 21 March 2022
Accepted: 18 May 2022
Published: 19 May 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract: Neoadjuvant short course radiotherapy (SCRT) followed by consolidation chemotherapy (CCT) is an alternative treatment for locally advanced rectal cancer (LARC). We performed this systematic review and meta-analysis to explore the tumor response and oncological outcomes of this new approach compared to conventional chemoradiotherapy (CRT). An online search of the PubMed, Embase, and Cochrane Library databases was performed. This review included 7507 patients from 14 different cohorts. The pCR rate was higher with SCRT + CCT than that with CRT (RR: 1.60; 95% CI: 1.35–1.91; p < 0.01). SCRT + CCT provided a higher ypN0 response (RR: 1.06; 95% CI: 1.01–1.12; p = 0.02). There were no differences in R0 resection and positive CRM rates; however, more sphincter-preservation surgeries were performed in the SCRT + CCT arm (RR: 1.06; 95% CI: 1.01–1.11; p = 0.02). There was no difference in the OS and DFS between the SCRT + CCT and the CRT arms (OS: HR: 0.85, p = 0.07; DFS: HR: 0.88, p = 0.08). The compliance and toxicity were comparable between the SCRT and CRT groups. In the subgroup analysis, patients who underwent four or more cycles of CCT had better pCR and DFS events. Therefore, SCRT followed by consolidation chemotherapy might be an effective alternative treatment for LARC.

Keywords: rectal cancer; short course radiotherapy; consolidation chemotherapy; pathological complete response; overall survival; disease free survival; meta-analysis

1. Introduction

Colorectal cancer (CRC) is the third most common cancer and the second leading cause of cancer-related deaths worldwide. According to GLOBOCAN statistics, there were over 1.9 million new CRC cases in 2020, with 39% in the rectum [1]. After the introduction of total mesorectal excision (TME) by Dr. Heald in the 1980s, the local recurrence rate of rectal cancer decreased to 4–9%, and survival reached 75–80% [2,3]. Several randomized trials have revealed that adding preoperative radiotherapy or chemoradiation improves the local recurrence rate to approximately 5% [4,5]. Therefore, surgical treatment with TME after neoadjuvant chemoradiation has become the standard treatment for locally advanced rectal cancers (LARC). In the past two decades, short-course radiotherapy (SCRT) with immediate surgery or concurrent chemoradiotherapy (CRT) with surgery four to
six weeks later has been recommended by guidelines worldwide [6,7]. Despite different interpretations of treatment efficacy, several large trials have revealed the same local control and overall survival between these two approaches [8,9]. Good local control was observed in the neoadjuvant treatment of locally advanced rectal cancer. However, distal metastasis is still reported in approximately 30% of cases [9,10]. Therefore, a new treatment strategy to reduce early metastasis is urgently needed. A criticism of using SCRT with immediate surgery for LARC is that a short interval precludes the possibility of clinical tumor response and organ preservation. Recently, the Stockholm III trial showed a 10.1% tumor response rate if the interval between SCRT and surgery was increased to four to eight weeks, and the safety of delayed surgery was reported to be similar to that of in comparison with immediate surgery [11,12]. Following this result, many studies have been conducted to explore the effectiveness and feasibility of SCRT with delayed surgery and conventional CRT [11–13]. However, another concern is that there is no protection from chemotherapy during this long waiting interval. Therefore, it is reasonable to propose the addition of consolidation chemotherapy during this period as a new neoadjuvant treatment modality. Recently, an increasing number of studies have compared SCRT and consolidation chemotherapy with conventional CRT for the treatment of LARC [14–16]. The aim of this systematic review and meta-analysis is to summarize current evidence regarding neoadjuvant SCRT followed by consolidation chemotherapy before surgery for LARC, and explore the efficacy in tumor response, treatment toxicity, surgical complications, patient compliance, overall survival (OS), and disease-free survival (DFS). Furthermore, we included studies comparing SCRT with delayed surgery and conventional CRT to understand the effectiveness of consolidation chemotherapy.

2. Material and Methods

2.1. Search Strategy

This study was conducted in accordance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis [17]. A comprehensive search was conducted using the PubMed, Embase, and Cochrane Library databases from the earliest records to 31 March 2022. The search terms were as follows: (rectal cancer or rectal neoplasm) AND (preoperative) AND (short-course radiotherapy) AND (long-course chemoradiation or long-course radiotherapy). Two reviewers independently searched the databases for eligible articles. The bibliographies of the included trials and related review articles were manually reviewed for potentially missing studies. The protocol of this systematic review was registered in PROSPERO with the registration ID CRD42021250641.

2.2. PICOS-Based Inclusion and Exclusion Criteria

The inclusion criteria were designed according to the Population, Intervention, Comparison, Outcomes, and Study (PICOS) design principle and were set as follows: (1) P: patients with pathologically proven rectal cancer; (2) I: neoadjuvant SCRT, composed of a total dose of 25 Gy, followed by delayed surgery after at least four weeks, with or without consolidation chemotherapy during the waiting period; (3) C: neoadjuvant conventional CRT, composed of a total dose of 50–50.4 Gy, followed by delayed surgery after at least four weeks, with or without consolidation chemotherapy during the waiting period; (4) O: pathological complete response (pCR) rate, tumor downstaging rate, radiotherapy or chemotherapy-related grade 3/4 acute toxicity and/or late toxicity, sphincter-preservation rate, post-operative complications (anastomosis leakage, surgical site infection, and ileus), R0 resection rate, CRM free rate, overall survival, disease-free survival, local recurrence, distant metastasis, and compliance with treatment (chemotherapy or radiotherapy). Studies reporting these outcomes were included; (5) S: randomized controlled trials (RCTs) or observational studies.

The exclusion criteria were as follows: (1) patients with synchronous metastasis during diagnosis; (2) radiotherapy not meeting the inclusion criteria; (3) delay between radiotherapy and surgery was less than four weeks; (4) lack of qualified data for extraction.
and analysis; (5) single-arm studies, review articles, case reports, editorials, comments, or conference abstracts.

2.3. Data Extraction and Quality Assessment

Two independent reviewers examined all retrieved articles and extracted data using a predetermined form. The following information was extracted: (1) characteristics of the study: author name, publication year, study period, location, and study type; (2) characteristics of the study cohort: patient number, age, sex, stage, tumor location, intervention (including RT dose, chemotherapy regimen, surgery type, and adjuvant chemotherapy), and follow-up time; (3) outcomes: pCR rate, downstaging rate, sphincter preservation rate, R0 resection rate, grade 3/4 acute toxicity (during neoadjuvant treatment), postoperative grade 3/4 complications, late toxicity, compliance with treatment (including RT and chemotherapy), local recurrence, distant metastasis, OS, and DFS. Inconsistencies between the two reviewers were resolved through discussions. The risk of bias was assessed by two reviewers and all discrepancies were resolved after consensus with the corresponding author. We used the Cochrane risk of bias assessment tool 2.0 to evaluate the quality of RCTs. The tool contained five domains, including bias in the randomization process, deviations from the intended interventions, missing outcome data, bias in the measurement of the outcomes, and selection of the reported result. Each domain was assessed as low and high risk of bias, or as that having some concern [18]. The quality of the observational studies was assessed using the Newcastle–Ottawa Quality Assessment Scale (NOS). NOS contains nine items in three categories: participant selection (four items), comparability (two items), and exposure (three items). A study can be scored a maximum of one point for each item in the selection and exposure domains and two points for the comparability domain [19]. A study with a NOS score of seven or higher was defined as a high-quality study.

2.4. Statistical Analysis

All statistical analyses were performed using Review Manager (RevMan version 5.4) from the Cochrane Collaboration. The categorized variables were calculated using the Mantel-Haenszel method and presented as risk ratios (RRs). Survival analysis was calculated using the inverse variance method using the hazard ratio (HR) and 95% confidence interval (CI) extracted directly from the original studies while reporting survival analysis of OS or DFS. We also analyzed OS, DFS, local recurrence (LR), and distant metastasis (DM) at a reported time point using the Mantel-Haenszel method and presented them as risk ratios (RRs). Heterogeneity between the studies was determined using the Cochran Q-test and I² statistics. Considerable heterogeneity was defined as I² ≥ 50%. A random-effects model was used in this meta-analysis owing to a difference in the study design and the enrolled participants. A subgroup analysis was performed to investigate the pooled effect with or without consolidation chemotherapy after SCRT and cycles of consolidation chemotherapy.

2.5. Interpretation

The SCRT group (with or without CCT) was set as the experimental arm and the CRT group was set as the control arm in this meta-analysis. The comparisons measured the ratio of experimental arm versus control arm. Thus, when the outcome represented as RRs, the value greater than one means a higher rate of events in the SCRT group. When the outcome is represented as HRs, which was used in the survival analysis, a value greater than one means that the survival is worse in the SCRT group.

3. Results

3.1. Study Selection

A total of 636 articles were identified based on the online databases and manual searches, of which 218 duplicate records were removed. After reviewing the titles and abstracts of the articles, 344 were removed. After assessing the full text of the remaining 74 articles, 57 were excluded owing to 18 single-arm studies, five reviews, 19 conference
papers, three study protocols, 10 had incomplete data, and two had duplicated data. Finally, 17 eligible studies were included in the meta-analysis. The flow diagram is shown in Figure 1.

Figure 1. Preferred reporting items for systematic reviews and meta-analyses flow diagram to search and identify included studies.

### 3.2. Characteristics of the Included Study

Seventeen studies enrolling 7507 rectal cancer patients from 13 cohorts were included in this meta-analysis [13–16,20–32]. Of these, two studies reported different parameters of the same cohort [28,29], four studies reported survival outcomes at different time points [13,14,20,24], and one study reported an expanded enrollment including the preliminary cohort [31]. All studies were published between 2015 and 2022; of these, ten were RCTs, two were prospective studies, and five were retrospective studies. In summary, four cohorts from five studies compared SCRT with delayed surgery (n = 803) and conventional CRT (n = 4075) [13,20–23], and nine cohorts from 12 studies compared SCRT followed by consolidation chemotherapy with delayed surgery (n = 1452) and conventional CRT (n = 1452) [14–16,24–32]. The characteristics of the included studies are summarized in Table 1.

| Study Enrollment Years | Study Design | Staging | Intervention | Patient Numbers (male%) | Age (Years) | RT Dose | CT Regimen | Interval (Weeks) | ACT Regimen (Completion%) | Follow Up Time (Months) |
|------------------------|--------------|---------|--------------|-------------------------|-------------|---------|------------|----------------|---------------------------|-----------------------|
| Latkauskas 2016 [13]   | RCTs         | II–III  | SCRT         | 68 (63%)                | 65.6        | 25      | No         | 6–8            | Infusion 5FU/LV (72%)     | 39.7                  |
|                        |              |         | CRT          | 72 (68%)                | 63.1        | 50      | Infusion 5FU/LV | 6–8            | Infusion 5FU/LV (72%)     |                       |
| Kairevičė 2017 [20]    | RCTs         | II–III  | SCRT         | 68 (63%)                | 65.6        | 25      | No         | 6–8            | Infusion 5FU/LV (72%)     | 60.5                  |
|                        |              |         | CRT          | 72 (68%)                | 63.1        | 50      | Infusion 5FU/LV | 6–8            | Infusion 5FU/LV (72%)     |                       |
Table 1. Cont.

| Study               | Enrollment Years | Study Design | Staging  | Intervention | Patient Numbers (male%) | Age (Years) | RT Dose | CT Regimen | Interval (Weeks) | ACT Regimen (Completion%) | Follow Up Time (Months) |
|---------------------|------------------|--------------|----------|--------------|------------------------|-------------|---------|------------|-------------------|---------------------------|------------------------|
| Bujko 2016 [14]     | 2008–2014 RCTs   | cT3–4        | SCRT     | FOLFOX × 3   | 261 (70%)              | 60          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 12 | oxaliplatin-based (15%) oxaliplatin-based (11%) | 35                     |
| Ciseł 2019 [24]     | 2008–2014 RCTs   | cT3–4        | SCRT     | FOLFOX × 3   | 261 (70%)              | 60          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 12 | No                     | 7 years                |
| Beppu 2015 [25]     | 2008–2014 RCTs   | cT3–4        | SCRT     | FOLFOX × 3   | 261 (70%)              | 60          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 6  | No                     | 44                     |
| Chung 2017 [16]     | 2008–2014 RCTs   | cT3–4        | SCRT     | FOLFOX × 3   | 261 (70%)              | 60          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 6  | No                     | 45                     |
| Markovina 2017 [15] | 2009-2012 Phase II trial | cT3–4    | SCRT     | FOLFOX × 6   | 69 (71%)               | 57.2        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | NA (86%)                | 49.4                   |
| Chapman 2022 [31]   | 2009-2018 retrospective II–III | SCRT     | FOLFOX × 6   | 69 (71%)               | 57.2        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | NA (60.1%)              | 28.3                   |
| Hoendervangers 2018 [21] | 2008-2014 retrospective II–III | SCRT     | FOLFOX × 6   | 69 (71%)               | 57.2        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | NA (60.1%)              | 41.6                   |
| Xiao 2018 [22]      | 2014-2017 RCTs   | II–III       | SCRT     | FOLFOX × 6   | 98 (48%)               | 49.6        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 6  | NA                     | 6.4 years              |
| Aghili 2020 [26]    | 2016–2020 RCTs   | II–III       | SCRT     | FOLFOX × 6   | 33 (55%)               | 56          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 8  | CAPOX or FOLFOX           | 5FU/LV                |
| Hoendervangers 2020 [23] | 2014–2017 RCTs   | II–III       | SCRT     | FOLFOX × 6   | 246 (58%)              | 76.7        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 4.6 years              |
| Thakur 2020 [27]    | 2015–2016 Prospective | cT3–4    | SCRT     | FOLFOX × 6   | 15 (25%)               | 75.9        | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 2.4 years              |
| van der Valk 2020 [28] | 2011–2016 RCTs  | cT4, cN2     | SCRT     | FOLFOX × 6   | 460 (65%)              | 61          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 4.6 years              |
| Bahadoer 2020 [29]  | 2011–2016 RCTs   | cT4, cN2     | SCRT     | FOLFOX × 6   | 462 (65%)              | 62          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 4.6 years              |
| Chakrabarti 2021 [30] | 2017–2019 RCTs   | II–III       | SCRT     | FOLFOX × 6   | 67 (69%)               | 42          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 6.8 years              |
| Jin 2022 [32]       | 2015–2018 RCTs   | II–III       | SCRT     | FOLFOX × 6   | 302 (72%)              | 55          | 25      | Infusion   5FU/LV + Oxaliplatin × 2 | 4  | CAPOX or FOLFOX           | 6.8 years              |

* cT4a/b, cN2, EMVI, mesorectal fascia involvement, and LLN+. NA: “Not available.”

3.3. Quality Analysis

All of the included RCTs in this study reported the randomization process; however, patients were informed regarding their treatment plan at allocation because of the difficulty in keeping the radiotherapy regimen a secret between the patients and researchers. However, the above restriction did not affect the outcome assessment. Considering deviations from the intended interventions, there was a disproportion regarding completion of the
intended adjuvant chemotherapy. In most studies, adjuvant chemotherapy was optional after CRT; thus, there was heterogeneity in the control group. The patients with or without adjuvant chemotherapy may influence the outcomes. As a result, “some concerns” was graded for all the RCTs in “deviations from the intended interventions” section. The risk of bias graphs and summary is shown in Figure 2. The quality of the seven cohort studies was evaluated using the Newcastle-Ottawa Scale (NOS). As shown in Table 2, the NOS scores of the included studies ranged from 7 to 9; therefore, they were regarded as being of high-quality.

### Risk of bias assessment and summary of the RCTs

| Study              | D1 | D2 | D3 | D4 | D5 | Overall |
|--------------------|----|----|----|----|----|---------|
| Latkauskas 2016    | +  | -  | +  | +  | +  | -       |
| Kairevičė 2017     | +  | -  | +  | +  | +  | -       |
| Bujko 2016         | +  | -  | +  | +  | +  | -       |
| Cisel 2019         | +  | -  | +  | +  | +  | -       |
| Xiao 2018          | +  | -  | +  | +  | +  | -       |
| Aghili 2020        | +  | -  | +  | +  | +  | -       |
| van der Valk 2020  | +  | -  | +  | +  | +  | -       |
| Bahadoer 2020      | +  | -  | +  | +  | +  | -       |
| Chakrabarti 2021   | +  | -  | +  | +  | +  | -       |
| Jin 2022           | +  | -  | +  | +  | +  | -       |

**Domains:**
- D1: Bias arising from the randomization process.
- D2: Bias due to deviations from intended intervention.
- D3: Bias due to missing outcome data.
- D4: Bias in measurement of the outcome.
- D5: Bias in selection of the reported result.

**Judgement**
- Yellow: Some concerns
- Green: Low

---

### Figure 2. Risk of bias (A) assessment and (B) summary of the RCTs.
### Table 2. Scores of the observational studies according to the Newcastle-Ottawa Scale.

| Author               | Selection Representativeness of the Exposed Cohort | Selection of the Nonexposed Cohort | Ascertainment of Exposure | Demonstration That the Outcome of Interest Was Not Present at the Start of the Study | Comparability of Cohorts Based on the Design or Analysis | Assessment of Outcome | Was Follow-Up Long Enough for Outcomes to Occur | Adequacy of the Follow-Up of Cohorts | NOS |
|----------------------|----------------------------------------------------|------------------------------------|---------------------------|--------------------------------------------------------------------------------|----------------------------------------------------------|---------------------|-----------------------------------------------|-------------------------------------|-----|
| Beppu 2015 [25]      | 1                                                  | 1                                  | 1                         | 1                                                                               | 1                                                          | 1                   | 1                                            | 1                                  | 8   |
| Chung 2017 [16]      | 1                                                  | 1                                  | 1                         | 1                                                                               | 1                                                          | 0                   | 1                                            | 1                                  | 7   |
| Markovina 2017 [19]  | 1                                                  | 1                                  | 1                         | 1                                                                               | 2                                                          | 1                   | 1                                            | 1                                  | 9   |
| Hoendervangers 2018 [21] | 1                                              | 1                                  | 1                         | 1                                                                               | 1                                                          | 0                   | 1                                            | 1                                  | 7   |
| Hoendervangers 2020 [23] | 1                                              | 1                                  | 1                         | 1                                                                               | 1                                                          | 0                   | 1                                            | 1                                  | 7   |
| Thakur 2020 [27]     | 1                                                  | 1                                  | 1                         | 1                                                                               | 1                                                          | 0                   | 1                                            | 1                                  | 7   |
| Chapman 2022 [31]    | 1                                                  | 1                                  | 1                         | 1                                                                               | 1                                                          | 1                   | 1                                            | 1                                  | 8   |

### 3.4. Tumor Response and pCR Rate

The details of the outcomes are summarized in Table 3. All studies provided data for analyzing the pCR rates. As shown in Figure 3, SCRT followed by consolidation chemotherapy provided a higher pCR rate compared to that with conventional CRT (RR: 1.60; 95% CI: 1.35–1.91, p < 0.01). In contrast, SCRT with delayed surgery and no consolidation chemotherapy had a lower pCR rate compared to that with conventional CRT (RR: 0.47; 95% CI: 0.35–0.63; p < 0.01). Regarding tumor downstaging, nine studies reported the comparison results, and there was no difference between SCRT + CCT and conventional CRT (RR: 1.04; 95% CI: 0.75–1.45; p = 0.81). However, lower downstaging was observed in the SCRT with delayed surgery group (RR: 0.82; 95% CI: 0.74–0.91; p < 0.01) (Figure S1). Regarding the ypT3-4 response, SCRT with CCT showed a better response than that with conventional CRT (RR: 0.87; 95% CI: 0.74–1.01; p = 0.07) (Figure S2). Regarding the ypN0 response, SCRT with CCT was better than conventional CRT (RR: 1.06; 95% CI: 1.01–1.12; p = 0.02) (Figure S3).

### Table 3. Summary of the outcomes from the including studies.

| Study       | Intervention | pCR Rate | Downstaging Rate | R0 Resection Rate | Sphincter Preservation | OS          | DFS          |
|-------------|--------------|-----------|------------------|-------------------|------------------------|-------------|--------------|
| Latkauskas 2016 [13] | SCRT         | 4.4       | 30.9             | 86.5              | 70.3                   | 78.0 (3-year)| 59.0 (3-year)|
| Kairevičė 2017 [20] | CRT          | 11.1      | 37.5             | 91.3              | 69.6                   | 82.4 (3-year)| 75.1 (3-year)|
| Bujko 2016 [14]     | SCRT         | 16        | NA               | 77                | 43                     | 73 (3-year) | 53 (3-year) |
| Cisel 2019 [24]     | SCRT         | 12        | NA               | 71                | 39                     | 65 (3-year) | 52 (3-year) |
| Beppu 2015 [25]     | SCRT         | 4.8       | 37.5             | NA                | 93.3                   | 95.1 (3-year)| 83.8 (3-year)|
| Chung 2017 [16]     | SCRT         | 21.1      | 47.4             | NA                | 89.5                   | 90 (2-year) | 93.8 (2-year)|
|                   | CRT          | 13.2      | 26.4             | NA                | 94.3                   | 91.2 (2-year)| 74.0 (2-year)|
| Study                  | Intervention | pCR Rate | Downstaging Rate | R0 Resection Rate | Sphincter Preservation | OS            | DFS            |
|-----------------------|--------------|----------|------------------|-------------------|------------------------|---------------|----------------|
| Markovina 2017 [15]   | SCRT         | 28       | 75               | NA                | 75.4                   | 96 (3-year)   | 85 (3-year) * |
|                       | CRT          | 16       | 41               | NA                | 72.5                   | 88 (3-year)   | 68 (3-year)   |
| Chapman 2022 [31]     | SCRT         | 26.2     | NA               | 94.2              | NA                     |               |                |
|                       | CRT          | 17.3     | NA               | 89.8              | 60.6                   | NA            | NA            |
| Hoendervangers 2018 [21] | SCRT       | 6.4      | 46.8             | NA                | 42.5                   | NA            | NA            |
|                       | CRT          | 16.2     | 56.1             | NA                | 51.7                   | NA            | NA            |
| Xiao 2018 [22]        | SCRT         | 7.14     | 21.43            | NA                | NA                     | NA            | NA            |
|                       | CRT          | 11.22    | 25.51            | NA                | NA                     | NA            | NA            |
| Aghili 2020 [26]      | SCRT         | 32.3     | 80.8             | 100               | 100                    | NA            | NA            |
|                       | CRT          | 23.1     | 84.6             | 96.2              | 96.2                   | NA            | NA            |
| Hoendervangers 2020 [23] | SCRT       | 7.7      | NA               | 91.9              | NA                     | NA            | NA            |
|                       | CRT          | 12.6     | NA               | 89                | NA                     | NA            | NA            |
| Thakur 2020 [27]      | SCRT         | 6.7      | 35.7             | 92.8              | 75                     | NA            | NA            |
|                       | CRT          | 0        | 53.8             | 92.3              | 62.5                   | NA            | NA            |
| Bahadoer 2020 [29]    | SCRT         | 28       | NA               | 90                | 63.6                   | 89.1 (3-year) | 23.7 (3-year DRTF) |
|                       | CRT          | 14       | NA               | 90                | 58.8                   | 88.8 (3-year) | 30.4 (3-year DRTF) |
| Chakrabarti 2021 [30] | SCRT         | 13.3     | 75.4             | 100               | 65                     | NA            | NA            |
|                       | CRT          | 10.9     | 74.6             | 100               | 59.4                   | NA            | NA            |
| Jin 2022 [32]         | SCRT         | 16.6     | NA               | 91.5              | 52.8                   | 86.5 (3-year) | 64.5 (3-year) |
|                       | CRT          | 11.7     | NA               | 87.8              | 56.1                   | 75.1 (3-year) | 62.3 (3-year) |

* DRTF: first occurrence of locoregional failure, distant metastasis, new primary colorectal tumor, or treatment-related death. NA: not available.
3.5. Overall Survival and Disease-Free Survival

A total of seven studies including 2533 patients reported the OS data at a fixed time point for assessment with a follow-up interval between 25 months and seven years. There was no statistical difference between SCRT with delayed surgery (RR: 0.86, 95% CI: 0.68–1.08, \( p = 0.19 \)) and conventional CRT, but a superior OS was observed in the SCRT + CCT (RR: 1.05; 95% CI: 1.00–1.11; \( p = 0.04 \)) arm by using RRs as the estimation (Figure 4). Regarding DFS, eight studies, including 2561 patients, reported DFS data at a fixed time point. SCRT + CCT led to significantly better DFS compared to conventional CRT (RR: 1.10; 95% CI: 1.04–1.17; \( p = 0.02 \)). In contrast, SCRT with delayed surgery had a worse DFS compared to that with conventional CRT (RR: 0.68; 95% CI: 0.50–0.93; \( p = 0.02 \)) (Figure 5).

Regarding the survival rate by hazard ratio, which was available and analyzed only in four RCTs, one in the SCRT with delayed surgery arm and three in the SCRT + CCT arm. The OS and DFS were superior in the conventional CRT arm to those in the SCRT with delayed surgery. A marginally significant effect favoring the SCRT with the CCT arm was observed. The OS (HR: 0.85; 95% CI: 0.71–1.01; \( p = 0.07 \)) and DFS (HR: 0.88; 95% CI: 0.77–1.012; \( p = 0.08 \)) were estimated by combining the three RCTs (Figures 6 and 7).
Figure 4. Forest plot of overall survival (OS) events by Risk ratio (RR).

Figure 5. Forest plot of disease-free survival (DFS) events by Risk ratio (RR).
with delayed surgery had a lower sphincter preservation rate compared to the CRT arm (RR: 1.01; 95% CI: 0.93–1.09; p = 0.87; 95% CI: 0.75–1.00; p = 0.26) and SCRT with delayed surgery or SCRT + CCT and conventional CRT (RR: 1.02; 95% CI: 0.99–1.05; p = 0.11) (Figure S6). The negative CRM rates were also similar between the SCRT and conventional CRT arms (RR: 1.00; 95% CI: 0.98–1.02; p = 0.80) (Figure S4). Regarding the incidences of DM, there was no statistical difference between SCRT + CCT and conventional CRT (RR: 0.86; 95% CI: 0.68–1.07; p = 0.18) (Figure S5).

### 3.6. R0 Resection, Negative CRM, Sphincter-Preservation Rate, and Postoperative Complications

Ten studies reported R0 resection rates for assessment, and there was no statistical difference between the SCRT and conventional CRT arms regarding R0 resection rates, either with delayed surgery (RR: 1.01; 95% CI: 0.93–1.09; p = 0.87) or consolidation chemotherapy (RR: 1.02; 95% CI: 0.99–1.05; p = 0.11) (Figure S6). The negative CRM rates were also similar between the SCRT and conventional CRT arms (RR: 1.00; 95% CI: 0.98–1.02; p = 0.90) (Figure S7). Regarding sphincter preservation rates, 11 studies enrolling 6753 patients offered data for assessment. SCRT + CCT had a superior sphincter preservation rate compared to conventional CRT (RR: 1.06; 95% CI: 1.01–1.11; p = 0.02). In contrast, SCRT with delayed surgery had a lower sphincter preservation rate compared to the CRT arm (RR: 0.86; 95% CI: 0.75–1.00; p = 0.05) (Figure 8). There was no difference in postoperative complications between SCRT with delayed surgery or SCRT + CCT and conventional CRT.

### Figure 6. Forest plot of the overall survival (OS) by Hazard ratio (HR).

### Figure 7. Forest plot of the disease free survival (DFS) by Hazard ratio (HR).

Data on the incidence of local recurrence and distant metastasis were reported in eight and seven studies, respectively. There was no statistical difference in LR between SCRT + CCT and conventional CRT (RR: 1.12; 95% CI: 0.91–1.37; p = 0.26) and SCRT with delayed surgery and conventional CRT (RR: 0.85; 95% CI: 0.24–3.02; p = 0.80) (Figure S4). Regarding the incidences of DM, there was no statistical difference between SCRT + CCT and conventional CRT (RR: 0.86; 95% CI: 0.68–1.07; p = 0.18) (Figure S5).
However, a borderline significance of RR was observed when the two models of SCRT were combined (RR: 1.10; 95% CI: 1.00–1.21; p = 0.06) (Figure S8).

### 3.7. Acute Toxicity, Late Toxicity, and Compliance of Treatment

Grade 3+ acute toxicity was reported by nine studies and no difference was observed between the SCRT + CCT and CRT arms (RR: 1.30; 95% CI: 0.91–1.85; p = 0.15), in contrast to a superior outcome in the SCRT with delayed surgery arm (RR: 0.19; 95% CI: 0.08–0.48; p < 0.001) (Figure S9). The incidences of grade 3+ late toxicity were only available in four studies, and the SCRT + CCT arm was worse compared to the CRT arm (RR: 1.32; 95% CI: 1.08–1.62; p = 0.008) (Figure S10A). The overall compliance with radiotherapy was better for SCRT with a 100% completion rate reported in five studies, in contrast to 1.8% to 7.7% of patients requiring dose reduction in the CRT arm. No difference in chemotherapy dose reduction was observed between the SCRT + CCT and CRT arms (RR: 1.12; 95% CI: 0.31–3.96; p = 0.87) (Figure S10B).

### 3.8. Subgroup Analysis according to the Consolidation Chemotherapy Cycle

The subgroup analysis showed a significantly better pCR rate with SCRT followed by at least four cycles of consolidation chemotherapy compared to the CRT arm (RR: 1.93; 95% CI: 1.52–2.45; p < 0.01). In contrast, no difference was observed in the SCRT arm as consolidation chemotherapy was administered in less than four cycles (RR: 1.32; 95% CI: 0.83–2.08; p = 0.24) (Figure 9). There was no difference between the SCRT and CRT arms regarding CCT cycles on OS events (Figure 10); however, significantly better DFS events were observed in CCT cycles ≥ 4 subgroups (RR: 1.13; 95% CI: 1.03–1.24; p = 0.01), and no difference was observed in the CRT arm with the CCT cycles < 4 subgroups (RR: 1.06; 95% CI: 0.94–1.20; p = 0.33) (Figure 11).
**Table 1:**

| Study or Subgroup | ScRT Events Total | CRT Events Total | Weight | Risk Ratio M-H, Random, 95% CI | Year |
|-------------------|-------------------|-----------------|--------|--------------------------------|------|
| **4.1.1 ScRT + CCT < 4 cycles** | | | | | |
| Beppu 2015        | 5 104             | 5 61            | 2.1%   | 0.59 [0.18, 1.94]             | 2015 |
| Cisel 2019        | 37 220            | 24 205          | 13.4%  | 1.44 [0.89, 2.31]             | 2019 |
| Thakur 2020       | 1 14              | 0 13            | 0.3%   | 2.80 [0.12, 63.20]            | 2020 |
| Chakrabarti 2021  | 8 60              | 7 64            | 3.4%   | 1.22 [0.47, 3.16]             | 2021 |
| **Subtotal (95% CI)** | 398              | 343            | 19.2%  | 1.28 [0.86, 1.90]             |      |
| Total events      | 51                | 36             |        |                                |      |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 2.11, df = 3 (P = 0.55); I^2 = 0% | | | |
| Test for overall effect: Z = 1.21 (P = 0.23) | | | |

**Figure 9:** Forest plot for subgroup analysis of the pathological complete response (pCR) according to consolidation chemotherapy cycles.

**Table 2:**

| Study or Subgroup | ScRT Events Total | CRT Events Total | Weight | Risk Ratio M-H, Random, 95% CI | Year |
|-------------------|-------------------|-----------------|--------|--------------------------------|------|
| **4.1.2 ScRT + CCT ≥ 4 cycles** | | | | | |
| Chung 2017        | 4 19              | 7 53            | 2.5%   | 1.59 [0.52, 4.84]             | 2017 |
| Aghili 2020       | 10 31             | 6 26            | 4.0%   | 1.40 [0.59, 3.33]             | 2020 |
| Bahadori 2020     | 120 423           | 57 398          | 37.8%  | 1.98 [1.49, 2.63]             | 2020 |
| Chapman 2022      | 49 187            | 39 226          | 21.9%  | 1.52 [1.05, 2.21]             | 2022 |
| Jin 2022          | 39 235            | 27 230          | 14.7%  | 1.41 [0.90, 2.23]             | 2022 |
| **Subtotal (95% CI)** | 895              | 933            | 80.8%  | 1.69 [1.39, 2.06]             |      |
| Total events      | 222               | 136            |        |                                |      |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 2.30, df = 4 (P = 0.68); I^2 = 0% | | | |
| Test for overall effect: Z = 5.31 (P < 0.00001) | | | |
| Total (95% CI)    | 1293              | 1276           | 100.0% | 1.60 [1.35, 1.91]             |      |
| Total events      | 273               | 172            |        |                                |      |
| Heterogeneity: Tau^2 = 0.00; Chi^2 = 5.95, df = 8 (P = 0.65); I^2 = 0% | | | |
| Test for overall effect: Z = 5.30 (P < 0.00001) | | | |
| Test for subgroup differences: Chi^2 = 1.54, df = 1 (P = 0.21); I^2 = 35.2% | | | |

**Figure 10:** Forest plot for subgroup analysis of the overall survival (OS) events according to consolidation chemotherapy cycles.
with additional mFOLFOX-6 cycles between conventional CRT and surgery was compared. The pCR rate was delayed for four to eight weeks after SCRT, and it could reach 11.8%, compared to 4.2% in the control group. According to previous studies, the effect on tumor response was insufficient evidence to draw a conclusion regarding the R0 resection rates, treatment toxicity, and complications. Although increasing pCR rates were also observed after SCRT with delayed surgery, the above parameters did not improve with an increased time interval before surgery compared to the conventional CRT.

The improved pCR rate might be attributed to the prolonged interval between radiotherapy, surgery, and the addition of systemic chemotherapy during this period. Regarding traditional neoadjuvant treatment, a criticism for applying SCRT with immediate surgery in LARC is that the short interval precludes the possibility of clinical tumor response. In the Stockholm III trial, the experimental arm showed an increasing pCR rate if surgery was delayed for four to eight weeks after SCRT, and it could reach 11.8%, compared to 2.1% in the SCRT with the immediate surgery group [11]. According to previous studies, an increasing pathological response was observed after SCRT with delayed surgery; however, the pCR rate was not greater than after conventional CRT [13,20–23]. Moreover, the pooled results in this meta-analysis showed a significantly lower pCR rate compared to conventional CRT in patients who underwent conventional CRT although there was insufficient evidence to draw a conclusion regarding the R0 resection rates, treatment toxicity, and complications. Although increasing pCR rates were also observed after SCRT with delayed surgery, the above parameters did not improve with an increased time interval before surgery compared to the conventional CRT.

The improved pCR rate might be attributed to the prolonged interval between radiotherapy, surgery, and the addition of systemic chemotherapy during this period. Regarding traditional neoadjuvant treatment, a criticism for applying SCRT with immediate surgery in LARC is that the short interval precludes the possibility of clinical tumor response. In the Stockholm III trial, the experimental arm showed an increasing pCR rate if surgery was delayed for four to eight weeks after SCRT, and it could reach 11.8%, compared to 2.1% in the SCRT with the immediate surgery group [11]. According to previous studies, an increasing pathological response was observed after SCRT with delayed surgery; however, the pCR rate was not greater than after conventional CRT [13,20–23]. Moreover, the pooled results in this meta-analysis showed a significantly lower pCR rate compared to conventional CRT in patients who underwent SCRT followed by delayed surgery without consolidation chemotherapy. Therefore, simply extending the interval between SCRT and surgery cannot replace conventional CRT in the treatment of LARC.

Previous studies have shown better long-term OS and DFS in patients with tumor regression or pCR after neoadjuvant treatment for LARC [33,34]. Adding systemic chemotherapy to neoadjuvant treatment was one proposal for improving tumor response. In a prospective phase II trial conducted by Garcia-Aguilar et al., the effect on tumor response with additional mFOLFOX-6 cycles between conventional CRT and surgery was compared. There was an obvious improvement in tumor response with increasing chemotherapy cycles, with a 25% pCR rate in two cycles of the mFOLFOX-6 group and up to 38% in six cy-

**Figure 11.** Forest plot for subgroup analysis of the disease free survival (DFS) events according to consolidation chemotherapy cycles.

### 4. Discussion

This meta-analysis demonstrated that treating LARC with SCRT followed by consolidation chemotherapy provides better pCR rates, results in more ypN0 status from positive pre-treatment lymph nodes, and increases sphincter preservation surgery. Moreover, improved tumor downstaging status owing to the lesser presentation of the ypT3-4 tumor after surgery and a trend of reduced distant metastasis were observed; the OS and DFS were comparable to those in patients who underwent conventional CRT although there was insufficient evidence to draw a conclusion regarding the R0 resection rates, treatment toxicity, and complications. Although increasing pCR rates were also observed after SCRT with delayed surgery, the above parameters did not improve with an increased time interval before surgery compared to the conventional CRT.

The improved pCR rate might be attributed to the prolonged interval between radiotherapy, surgery, and the addition of systemic chemotherapy during this period. Regarding traditional neoadjuvant treatment, a criticism for applying SCRT with immediate surgery in LARC is that the short interval precludes the possibility of clinical tumor response. In the Stockholm III trial, the experimental arm showed an increasing pCR rate if surgery was delayed for four to eight weeks after SCRT, and it could reach 11.8%, compared to 2.1% in the SCRT with the immediate surgery group [11]. According to previous studies, an increasing pathological response was observed after SCRT with delayed surgery; however, the pCR rate was not greater than after conventional CRT [13,20–23]. Moreover, the pooled results in this meta-analysis showed a significantly lower pCR rate compared to conventional CRT in patients who underwent SCRT followed by delayed surgery without consolidation chemotherapy. Therefore, simply extending the interval between SCRT and surgery cannot replace conventional CRT in the treatment of LARC.

Previous studies have shown better long-term OS and DFS in patients with tumor regression or pCR after neoadjuvant treatment for LARC [33,34]. Adding systemic chemotherapy to neoadjuvant treatment was one proposal for improving tumor response. In a prospective phase II trial conducted by Garcia-Aguilar et al., the effect on tumor response with additional mFOLFOX-6 cycles between conventional CRT and surgery was compared. There was an obvious improvement in tumor response with increasing chemotherapy cycles, with a 25% pCR rate in two cycles of the mFOLFOX-6 group and up to 38% in six cy-

### Table 1

| Study or Subgroup | SCRT + CCT < 4 cycles | SCRT + CCT ≥ 4 cycles |
|-------------------|-----------------------|-----------------------|
| **Events**         | **Total**             | **Total**             |
| Events             | Total                 | Weight               | Risk Ratio | Year |
| M-H, Random, 95% CI |                       |                       |            |     |
| Beppu 2015         | 87                    | 104                   | 48         | 61 | 13.8% | 1.06 [0.91, 1.24] | 2015 |
| Cisel 2019         | 115                   | 261                   | 107        | 254 | 8.8%  | 1.05 [0.86, 1.28] | 2019 |
| Thakur 2020        | 7                     | 15                    | 4          | 13  | 0.4%  | 1.52 [0.57, 4.04] | 2020 |
| Subtotal (95% CI)  | 380                   | 328                   | 230%       |     |       | 1.06 [0.94, 1.20] |     |

**Total events** 209, 159

Heterogeneity: TAU² = 0.00; CHI² = 0.53, df = 2 (P = 0.77); I² = 0%

Test for overall effect: Z = 0.98 (P = 0.33)

**Subtotal (95% CI)**

| Chung 2017         | 18                    | 19                    | 39         | 53  | 9.3%  | 1.29 [1.06, 1.56] | 2017 |
| Markovina 2017     | 59                    | 69                    | 47         | 69  | 9.7%  | 1.26 [1.04, 1.52] | 2017 |
| Bahadero 2020      | 334                   | 462                   | 298        | 450 | 36.8% | 1.09 [1.00, 1.19] | 2020 |
| Jin 2022           | 192                   | 298                   | 183        | 293 | 21.1% | 1.03 [0.91, 1.17] | 2022 |
| Subtotal (95% CI)  | 848                   | 865                   | 77.0%      |     |       | 1.13 [1.03, 1.24] |     |

**Total events** 603, 567

Heterogeneity: TAU² = 0.00; CHI² = 5.70, df = 3 (P = 0.13); I² = 47%

Test for overall effect: Z = 2.54 (P = 0.01)

**Total (95% CI)**

| Events             | Total                 | Weight               | Risk Ratio | Year |
|--------------------|-----------------------|----------------------|------------|------|
| 1228               | 1193                  | 100.0%               | 1.10       | 1.04 | 1.17 |

**Total events** 812, 726

Heterogeneity: TAU² = 0.00; CHI² = 6.61, df = 6 (P = 0.36); I² = 9%

Test for overall effect: Z = 3.17 (P = 0.002)

Test for subgroup differences: CHI² = 0.64, df = 1 (P = 0.42), I² = 0%
cles of the mFOLFOX-6 group [35]. This finding indicates the potential for tumor shrinkage if systemic chemotherapy is added to neoadjuvant treatment. Many studies have focused on the feasibility and safety of adding consolidation or induction chemotherapy to typical (chemo) radiotherapy. A better pCR rate and tumor response, including turning more lymph node-negative and having a less ypT3-4 stage, were observed in this meta-analysis, revealing the feasibility of SCRT with consolidation chemotherapy in treating LARC. With a better tumor response, more patients can undergo sphincter-preservation surgery with no increase in the complication rate compared to conventional CRT. The improved pCR rate and sphincter preservation surgery also indicate the potential of organ preservation treatment, including the “watch and wait” strategy [36,37].

Regarding the oncological outcome, this meta-analysis showed no difference in OS between SCRT and CRT, regardless of consolidation chemotherapy using an event-to-patient ratio. However, diverse DFS rates were observed. The pooled DFS events in SCRT followed by consolidation chemotherapy was better compared to conventional CRT. Because the above outcomes contain data from both observational studies and RCTs, the estimation may have a higher risk of bias and we should pay attention to these results. Considering the OS and DFS using the time-to-events ratio, only four RCTs provided the HRs for analysis. The study conducted by Kairevičė et al. revealed poorer OS and DFS in SCRT with a delayed surgery arm compared to that in the conventional CRT arm. This was foreseeable because only the CRT arm participants received adjuvant chemotherapy after surgery [20]. Three RCTs, from the Polish II, RAPIDO, and STELLAR trials, compared SCRT with consolidation chemotherapy and conventional CRT [14,29,32]. Although no significant difference in the pooled OS and DFS was observed, a trend favoring the SCRT + CCT arm was observed. However, these results should be interpreted cautiously owing to some obvious heterogeneities within these studies. First, the administration and completion of adjuvant chemotherapy varied across studies. Optional adjuvant chemotherapy was used in both arms in the Polish II trial in contrast to adjuvant chemotherapy usage only in the conventional CRT arm in the RAPIDO trial and in both arms in the STELLAR trial. In the Polish II trial, oxaliplatin-based chemotherapy was given in only 15% of the experimental group and 11% of the control group [14]. The completion rate of the scheduled dose of adjuvant chemotherapy was reported to be 47% in the RAPIDO trial and 48% in the STELLAR trial [28,32]. A recent study explored that adjuvant chemotherapy may improve the DFS in the RAPIDO trial by sensitivity analysis and indicated the decision of making adjuvant chemotherapy optional may have biased the results in favor of the experimental arm [38]. Another heterogeneity we should pay attention to is that the clinical stage of the enrolled patients differed among studies. The RAPIDO trial enrolled patients with mostly bulky tumors compared to the other two trials. The disparity regarding the trial design should be considered while examining the results of this meta-analysis.

The distinct chemotherapy regimens between the SCRT and CRT arms were also confounding factors influencing the oncological outcomes. Of the nine cohorts included for analysis, a combination of oxaliplatin and 5-FU based regiments was administered in seven cohorts and a single 5-FU based chemotherapy was used in the remaining two cohorts after SCRT compared to most studies that applied a single 5-FU agent in CRT. Several previous studies showed the effectiveness of adding oxaliplatin in neoadjuvant chemotherapy considering oncological outcomes. Marco et al. described the effect of two, four, or six cycles of mFOLFOX6 consolidation chemotherapy between CRT and TME surgery. There was no difference in OS; however, a significantly better DFS was found in patients who underwent CRT and consolidation chemotherapy [39]. Another study conducted by Liang et al., showed an improved pCR/near pCR rate (32.80% vs. 16.25%; p = 0.015) and 3-year DFS (85.48% vs. 56.54%; p = 0.036) in patients who received consolidation chemotherapy during the resting period between CRT and surgery [40]. The effect of adding oxaliplatin to a single agent, 5-FU, in neoadjuvant CRT was elucidated in a systematic review. Thavaneswaran et al., found that the combination regimen is superior to a single 5-FU agent regimen in terms of three-year DFS (HR: 0.79; 95% CI: 0.68–0.93; p = 0.004), LR (HR: 0.75;
95% CI: 0.58–0.97; \( p = 0.03 \), and DM rate (HR: 0.78; 95% CI: 0.64–0.96; \( p = 0.02 \)); however, it was not superior to OS (HR: 0.89; 95% CI: 0.75–1.06; \( p = 0.19 \)) [41].

Considering analysis of recurrence patterns, the pooled results were not significantly different between the SCRT with the CCT arm and CRT arms with regard to either local recurrence or distant metastasis in this meta-analysis. However, a trend towards more local recurrence events and less distant metastasis events in SCRT with the CCT arm was observed. In the updated five-year results of the RAPIDO trial, the author demonstrated increasing cumulative local recurrence rates (10% vs. 5%; \( p = 0.010 \)) and decreasing distant metastasis rates (23% vs. 31%, HR 0.72; \( p = 0.011 \)) in the experimental arm [42]. This indicates that a longer follow up time is warranted for exploring the effectiveness of the new treatment modality and for accurately interpreting the current data.

A meta-analysis showed a reduction in LR and DM and an increase in DFS if an oxaliplatin-based adjuvant chemotherapy was administered after CRT and TME surgery for rectal cancer patients than those that used a fluorouracil-based chemotherapy [43]. However, the OS did not differ between the two regimens. Thus, trinodal therapy, incorporating neoadjuvant treatment, TME, and adjuvant chemotherapy is now considered the standard treatment model for LARC. However, compliance with adjuvant chemotherapy is diverse across trials and has been reported to be between 43 and 73% [44]. Relatively improved compliance was observed in neoadjuvant treatment, another new treatment model, by shifting the adjuvant systemic chemotherapy before surgery. It was proposed and named "total neoadjuvant treatment" (TNT). Diefenhardt et al., conducted a post-hoc analysis of the CAO/ARO/AIO-04 trial and found that treatment adherence was associated with the three-year DFS. In the CRT with fluorouracil-oxaliplatin regimen arm, patients who underwent full-dose scheduled CRT had better DFS compared to those who underwent near-complete CRT (HR: 1.501; 95% CI: 0.980–2.299; \( p = 0.06 \)) and those who underwent reduced-dose CRT (HR, 1.724; 95% CI, 1.144–2.596; \( p = 0.009 \)). The above findings indicate the importance of treatment designs concerning the treatment dose, schedule, and any supportive strategies to facilitate good adherence [45], and support the rationale of using TNT in treating LARC.

In this meta-analysis, we found that compliance was good in the SCRT followed by the chemotherapy group. A 100% completion rate for SCRT was reported in each study, mainly because of the short treatment time required. Owing to the shorter treatment time, SCRT can increase patient convenience and reduce medical costs and is favored in many countries [46]. Compliance with consolidation chemotherapy depends on the regimen. In this meta-analysis, the pooled data regarding the incidence of reduced chemotherapy doses did not differ between the SCRT and CRT arms. However, the results showed high heterogeneity across studies, and careful interpretation should be performed. For grade 3+ acute toxicity, this meta-analysis showed no difference between SCRT followed by consolidation chemotherapy and the conventional CRT arm. However, the results varied across studies. The between-study differences may be attributed to the different chemotherapy regimens and cycles used. As previous studies showed a better tumor response and DFS with the addition of consolidation mFOLFOX-6 before surgery, a synchronized increase in the incidence of acute toxicity was also observed. In a meta-analysis by Thavaneswaran et al., acute grade 3/4 toxicity was common in the combination agent group (HR: 1.67; 95% CI: 1.21–2.31; \( p = 0.002 \), and radiotherapy compliance was lower compared to the single-agent group (HR: 0.41; 95% CI: 0.26–0.67; \( p = 0.0003 \)) [41]. In brief, the acute toxicity of consolidation chemotherapy increased with the cycles of the combination regimen administered, resulting in poor compliance with CRT. If we use SCRT instead of long course radiotherapy, we can minimize its influence on radiation compliance and achieve good treatment adherence. The last toxicity was less mentioned, and the assessed time varied in previous studies; therefore, the results that SCRT followed by consolidation chemotherapy leads to more late complications should be expounded carefully.

Currently, there is no consensus regarding the cycles of consolidation chemotherapy that should be administered before surgery. In the subgroup analysis of chemotherapy
cycles, we found a superior pCR rate and DFS events if four or more cycles of chemotherapy were applied. This finding is similar to that in previous studies that incorporated consolidation chemotherapy and CRT, which showed a superior pCR rate in patients who underwent six cycles of chemotherapy compared to those who underwent four or two cycles of chemotherapy [33,36]. Moreover, there is no consensus on whether induction or consolidation chemotherapy should be combined with radiotherapy. In the phase III PRODIGE 23 trial, an intensive chemotherapy regimen, FOLFIRINOX, was administered as induction chemotherapy before CRT and surgery. This experimental arm showed a 28% pCR rate and improved DFS compared to conventional CRT. Moreover, the incidence of neurotoxicity was lower in the adjuvant chemotherapy period compared to the control group. This finding convinced us that induction chemotherapy is more efficient and better tolerated compared to conventional CRT with adjuvant chemotherapy [47]. The phase III RAPIDO trial, which compared SCRT followed by consolidation mFOLFOX-6/CAPOX chemotherapy to conventional CRT, had a similar pCR rate (28%) as the PRODIGE 23 trial. Although considerable preoperative toxicity was noted compared to CRT, there was no difference in surgical complications [28,29].

Recently, the CAO/ARO/AIO-12 trial, which compared induction or consolidation chemotherapy with conventional CRT, reported a higher pCR rate in the consolidation group (25% vs. 17%; p < 0.001). Treatment toxicity and patient compliance were also more favorable in the consolidation group [48]. The long-term results showed no differences in OS, DFS, and incidences of LR and DM in both groups [49]. Therefore, the authors concluded that CRT followed by consolidation chemotherapy is the preferred TNT sequence if organ preservation is a priority. In a recent meta-analysis comparing TNT and standard therapy in LARC, TNT was associated with a high change in pCR (odds ratio: 2.44; 95% CI: 1.99–2.98; p < 0.001) [50]. However, the enrolled studies included chemotherapy combined with neoadjuvant SCRT and conventional CRT. There is still no evidence regarding which type of radiotherapy is better for TNT because no study has investigated a direct comparison. This meta-analysis focuses on the use of SCRT followed by consolidation chemotherapy because of several advantages regarding the use of SCRT. First, the shorter interval of treatment was convenient for patients and achieved good compliance. Second, medical costs are lower because of the shorter treatment duration. A randomized phase III trial, ACO/ARO/AIO-18.1 conducted by the German Rectal Cancer Study Group was proposed recently that compared SCRT and CRT, followed by consolidation chemotherapy and selective organ preservation for MRI-defined intermediate and high-risk rectal cancer patients [51]. The results of this RCT may answer the above questions.

There are some limitations to this study. First, the number of participants in most studies was small, and only three large RCTs included over 100 patients in each arm. Second, the regimen and cycles of consolidation chemotherapy varied across studies, limiting a conclusive result regarding which regimen is better. Third, although most studies enrolled patients with stage II-III rectal cancer, clinical heterogeneity remained, as tumor location varied across each study. Furthermore, studies that included patients that were at the advanced stage of the disease could also affect the results. Finally, the administration and completion of adjuvant chemotherapy varied across studies, even in the RCTs. This deviation in intervention may lead to a favorable result in the experimental arm. Moreover, survival events were reported at various follow-up times (25 months to seven years). Thus, our results should be interpreted carefully because the current data are not robust enough to set a strong conclusion. However, we believe that this meta-analysis provides an overview of the current evidence regarding the use of SCRT with delayed surgery and consolidation chemotherapy.

5. Conclusions

SCRT with delayed surgery can provide tumor control comparable to conventional CRT. Moreover, SCRT followed by consolidation chemotherapy can improve tumor downstaging and induce more pCR, which may help in sphincter-preservation surgery. However,
DFS, OS, toxicity, postoperative complications, and treatment compliance of the individuals were similar to those who underwent conventional CRT. Therefore, SCRT followed by consolidation chemotherapy can be considered as an alternative treatment for LARC. However, individuals should be treated according to the tumor pattern and their compliance.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/curroncol29050297/s1. Figure S1. Forest plot of down staging rate after neoadjuvant treatment. Figure S2. Forest plot of ypT3-4 rate after neoadjuvant treatment. Figure S3. Forest plot of ypN0 rate after neoadjuvant treatment. Figure S4. Forest plot of the rate of local recurrence. Figure S5. Forest plot of the rate of distant metastasis. Figure S6. Forest plot of the R0 resection rate. Figure S7. Forest plot of the negative circumferential resection margin (CRM) rate. Figure S8. Forest plot for the rate of postoperative complications. Figure S9. Forest plot of the rate of acute toxicity. Figure S10. Forest plot of (A) the rate of late toxicity (B) the compliance of chemotherapy.

Author Contributions: Conceptualization: C.-K.L. and Y.-T.K.; methodology: C.-K.L. and Y.-T.K.; software: C.-K.L., Y.-C.L. and Y.-J.C.; validation: C.-K.L., Y.-J.H. and Y.-L.Y.; formal analysis, C.-K.L. and P.-S.H.; investigation, J.-M.C. and Y.-T.K.; resources, Y.-C.L.; data curation, C.-K.L. and Y.-T.K.; writing—original draft preparation, C.-K.L.; writing—review and editing, C.-Y.Y. and J.-F.Y.; visualization, C.-K.L.; supervision, J.-M.C. and J.-F.Y.; project administration, J.-F.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare that they have no competing interests.

References

1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: Globocan Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef] [PubMed]

2. Heald, R.J.; Ryall, R.D.H. Recurrence and Survival after Total Mesorectal Excision for Rectal Cancer. Lancet 1986, 327, 1479–1482. [CrossRef] [PubMed]

3. Yoo, R.N.; Kim, H.J. Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy. Ann. Gastroenterol. Surg. 2019, 3, 356–367. [CrossRef] [PubMed]

4. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N. Engl. J. Med. 1997, 336, 980–987. [CrossRef] [PubMed]

5. Peeters, K.C.; Marijnens, C.; Nagtegaal, I.; Kranenbarg, E.M.-K.; Putter, H.; Wiggers, T.; Rutten, H.; Pahlman, L.; Glimelius, B.; Leer, J.W.; et al. The TMF Trial After a Median Follow-up of 6 Years. Ann. Surg. 2007, 246, 693–701. [CrossRef]

6. Benson, A.B.; Venook, A.P.; Al-Hawary, M.M.; Arain, M.A.; Chen, Y.-J.; Ciombor, K.K.; Cohen, S.; Cooper, H.S.; Deming, D.; Garrido-Laguna, I.; et al. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020: Featured Updates to the NCCN Guidelines. J. Natl. Compr. Cancer Netw. 2020, 18, 806–815. [CrossRef]

7. Glynne-Jones, R.; Wyrwicz, L.; Tietr, E.; Brown, G.; Rödel, C.; Cervantes, A.; Arnold, D. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2017, 28, iv22–iv40. [CrossRef]

8. Bujko, K.; Nowacki, M.P.; Nasierowska-Guttmejer, A.; Michalski, W.; Bebenek, M.; Kryj, M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 2006, 93, 1215–1223. [CrossRef]

9. Ngan, S.Y.; Burmeister, B.; Fisher, R.J.; Solomon, M.; Goldstein, D.; Ackland, S.P.; Schache, D.; McClure, B.; McLachlan, S.; et al. Randomized Trial of Short-Course Radiotherapy Versus Long-Course Chemoradiation Comparing Rates of Local Recurrence in Patients with T3 Rectal Cancer: Trans-Tasman Radiation Oncology Group Trial 01.04. J. Clin. Oncol. 2012, 30, 3827–3833. [CrossRef]

10. Sauer, R.; Liersch, T.; Merkel, S.; Fietkau, R.; Hohenberger, W.; Hess, C.; Becker, H.; Raab, H.-R.; Villanueva, M.-T.; Witzigmann, H.; et al. Preoperative Versus Postoperative Chemoradiotherapy for Locally Advanced Rectal Cancer: Results of the German CAO/ARO/AIO-94 Randomized Phase III Trial After a Median Follow-Up of 11 Years. J. Clin. Oncol. 2012, 30, 1926–1933. [CrossRef]

11. Pettersson, D.; Lörinc, E.; Holm, T.; Iversen, H.; Cedermark, B.; Glímélïus, B.; Martling, A. Tumour regression in the randomized Stockholm III Trial of radiation regimens for rectal cancer. Br. J. Clin. Oncol. 2015, 102, 972–978. [CrossRef] [PubMed]

12. Erlandsson, J.; Holm, T.; Pettersson, D.; Berglund, A.; Cedermark, B.; Radu, C.; Johansson, H.; Machado, M.; Hjern, F.; Hallböök, O.; et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): A multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol. 2017, 18, 336–346. [CrossRef]
13. Latkauskas, T.; Pauzas, H.; Kairevičė, L.; Petrauskas, A.; Saladžiškienė, Z.; Jančiauskienė, R.; Gudaitytė, J.; Lidzienis, P.; Svagzdys, S.; Tamelis, A.; et al. Preoperative conventional chemoradiotherapy versus short-course radiotherapy with delayed surgery for rectal cancer: Results of a randomized controlled trial. BMC Cancer 2016, 16, 927. [CrossRef] [PubMed]

14. Bujko, K.; Wyrwicz, L.; Rutkowski, A.; Malinowska, M.; Pietrzak, L.; Kryński, J.; Michalski, W.; Oledzki, J.; Kuśnierz, J.; Zajac, L.; et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: Results of a randomized phase III study. Ann. Oncol. 2016, 27, 834–842. [CrossRef]

15. Markovina, S.; Yousef, F.; Roy, A.; Aggarwal, S.; Khwaja, S.; DeWees, T.; Tan, B.; Hunt, S.; Myerson, R.J.; Chang, D.T.; et al. Improved Metastasis- and Disease-Free Survival with Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared with Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis. Int. J. Radiat. Oncol. Biol. Phys. 2017, 99, 417–426. [CrossRef]

16. Chung, M.J.; Kim, D.W.; Chung, W.K.; Lee, S.H.; Jeong, S.K.; Hwang, J.K.; Jeong, C.S. Preoperative short- vs. long-course chemoradiotherapy with delayed surgery for locally advanced rectal cancer. Oncotarget 2016, 8, 60479–60486. [CrossRef]

17. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 88, 105906. [CrossRef]

18. Sterne, J.A.C.; Savović, J.; Page, M.J.; Elbers, R.G.; Blencowe, N.S.; Boutron, I.; Cates, C.J.; Cheng, H.Y.; Corbett, M.S.; Eldridge, S.M.; et al. Rob 2: A revised tool for assessing risk of bias in randomised trials. BMJ 2019, 366, l4898. [CrossRef]

19. Stang, A. Critical of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur. J. Epidemiol. 2021, 25, 603–605. [CrossRef]

20. Kairevičė, L.; Latkauskas, T.; Tamelis, A.; Petrauskas, A.; Paužas, H.; Žvirblis, T.; Jaruševičius, L.; Saladžiškienė, Z.; Pavalkis, D.; Janciauskiene, R. Preoperative Long-Course Chemoradiotherapy plus Adjuvant Chemotherapy versus Short-Course Radiotherapy without Adjuvant Chemotherapy Both with Delayed Surgery for Stage II–III Resectable Rectal Cancer: 5-Year Survival Data of a Randomized Controlled Trial. Medicina 2017, 53, 150–158. [CrossRef]

21. Hoendervangers, S.; Couwenberg, A.M.; Intven, M.P.W.; van Grevenstein, W.M.U.; Verkooijen, H.M. Comparison of Pathological Complete Response Rates after Neoadjuvant Short-Course Radiotherapy or Chemoradiation Followed by Delayed Surgery in Locally Advanced Rectal Cancer. Eur. J. Surg. Oncol. 2018, 44, 1013–1017. [CrossRef] [PubMed]

22. Xiao, J.; Teng, W.H.; Liu, S.; Wei, C.; Liu, W.J.; Chen, S.; Zang, W.D. Short-course radiotherapy with delayed surgery versus conventional chemoradiotherapy: Comparison of short-term outcomes in patients with T3–4 rectal cancer. Int. J. Clin. Exp. Med. 2018, 11, 12149–12156. [CrossRef]

23. Hoendervangers, S.; Sparreboom, C.L.; Intven, M.P.W.; Lange, J.F.; Verkooijen, H.M.; Doornebosch, P.G.; Grevenstein, W.M.U.; the Dutch ColoRectal Audit. The Effect of Neoadjuvant Short-Course Radiotherapy and Delayed Surgery versus Chemoradiation on Postoperative Outcomes in Locally Advanced Rectal Cancer Patients—A Propensity Score Matched Nationwide Audit-Based Study. Eur. J. Surg. Oncol. 2020, 46, 1605–1612. [CrossRef] [PubMed]

24. Ciseł, B.; Pietrzak, L.; Michalski, W.; Wyrwicz, L.; Rutkowski, A.; Kosakowska, E.; Cencelewicz, A.; Spalek, M.; Polkowsi, W.; Jankiewicz, M.; et al. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: Long-term results of the randomized Polish II study. Ann. Oncol. 2019, 30, 1298–1303. [CrossRef]

25. Beppu, N.; Matsubara, N.; Noda, M.; Yamano, T.; Tsukada, A.; Doi, H.; Kamikonya, N.; Kimura, Y.; Yamane, N.; Yanagi, H.; et al. Short-Course Radiotherapy with Delayed Surgery versus Conventional Chemoradiotherapy: A Comparison of the Short- and Long-Term Outcomes in Patients with T3 Rectal Cancer. Surgery 2015, 158, 225–235. [CrossRef]

26. Aghi, M.; Khalili, N.; Khalili, N.; Babaei, M.; Farhan, F.; Haddad, P.; Salavand, S.; Keshvari, A.; Fazeli, M.S.; Mohammadi, N.; et al. Short-course versus Long-Course Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: Preliminary Results of a Randomized Controlled Trial. Radiat. Oncol. J. 2020, 38, 119–128. [CrossRef]

27. Thakur, N.; Seam, R.K.; Gupta, M.K.; Gupta, M.; Fotedar, V.; Vats, S.; Rana, S.; Vyas, P.; Ahuja, R. A Prospective Observational Study Comparing Long-Course Conventional Neoadjuvant Chemoradiotherapy with Short-Course Radiotherapy Followed by Consolidation Chemotherapy with Delayed Surgery in Locally Advanced Rectal Cancer. South Asian J. Cancer 2020, 9, 80–85. [CrossRef]

28. van der Valk, M.J.; Marijen, C.A.; van Etten, B.; Dijkstra, E.A.; Hilling, D.E.; Kranenburg, E.M.-K.; Putter, H.; Roedvoets, A.G.; Bahadero, R.R.; Fokstuen, T.; et al. Compliance and Tolerability of Short-Course Radiotherapy Followed by Preoperative Chemotherapy and Surgery for High-Risk Rectal Cancer—Results of the International Randomized RAPIDO-Trial. Radiother. Oncol. 2020, 147, 75–83. [CrossRef]

29. Bahadero, R.R.; Dijkstra, A.E.; van Etten, B.; Marijen, C.A.M.; Putter, H.; Kranenburg, E.M.-K.; Roedvoets, A.G.H.; Nagtegaal, I.D.; Beets-Tan, R.G.H.; Blomqvist, L.K.; et al. Short-Course Radiotherapy Followed by Chemotherapy before Total Mesorectal Excision (TME) versus Preoperative Chemoradiotherapy, TME, and Optional Adjuvant Chemotherapy in Locally Advanced Rectal Cancer (RAPIDO): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2021, 22, 29–42. [CrossRef]

30. Chakraborti, D.; Rajan, S.; Akhtar, N.; Qayoom, S.; Gupta, S.; Verma, M.; Srivastava, K.; Kumar, V.; Bhatt, M.L.B.; Gupta, R. Short-Course Radiotherapy with Consolidation Chemotherapy versus Conventionally Fractionated Long-Course Chemoradiotherapy for Locally Advanced Rectal Cancer: Randomised Clinical Trial. Br. J. Surg. 2021, 108, 511–520. [CrossRef]
31. Chapman, W.C.; Kim, H.; Bauer, P.; Makhdoom, B.A.; Trikalinos, N.A.; Pedersen, K.S.; Glasgow, S.C.; Mutch, M.G.; Silviera, M.L.; Roy, A.; et al. Total Neoadjuvant Therapy with Short-Course Radiation: US Experience of a Neoadjuvant Rectal Cancer Therapy. Dis. Colon Rectum 2022, 65, 198–206. [CrossRef] [PubMed]

32. Jin, J.; Tang, Y.; Hu, C.; Jiang, L.-M.; Jiang, J.; Li, N.; Liu, W.-Y.; Chen, S.-L.; Li, S.; Lu, N.-N.; et al. Multicenter, Randomized, Phase III Trial of Short-Term Radiotherapy Plus Chemotherapy Versus Long-Term Chemoradiation in Locally Advanced Rectal Cancer (STELLAR). J. Clin. Oncol. 2022, 40, JCO2101667. [CrossRef] [PubMed]

33. Sell, N.M.; Qwaider, Y.Z.; Goldstone, R.N.; Cauley, C.E.; Cusack, J.C.; Ricciardi, R.; Bordeianou, L.G.; Berger, D.L.; Kunitake, H. Ten-year Survival after Pathologic Complete Response in Rectal Adenocarcinoma. J. Surg. Oncol. 2021, 123, 293–298. [CrossRef] [PubMed]

34. Li, J.; Huang, X.; Song, Y.; Chen, X.; Lv, X.; Fu, Y.; Xiao, Q.; Ye, S.; Wang, Z. Survival Landscape of Different Tumor Regression Grades and Pathologic Complete Response in Rectal Cancer after Neoadjuvant Therapy Based on Reconstructed Individual Patient Data. BMC Cancer 2021, 21, 1214. [CrossRef] [PubMed]

35. Garcia-Aguilar, J.; Chow, O.S.; Smith, D.D.; Marcet, J.E.; Cataldo, P.A.; Varma, M.G.; Kumar, A.S.; Oommen, S.; Coutsoftides, T.; Hunt, S.R.; et al. Effect of Adding MFOLFOX6 after Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Multicentre, Phase 2 Trial. Lancet Oncol. 2015, 16, 957–966. [CrossRef]

36. van der Valk, M.J.; Hilling, D.; Bastiaannet, E.; Kransenbarg, E.M.-K.; Beets, G.L.; Figueiredo, N.; Habr-Gama, A.; O Perez, R.; Renehan, A.G.; van de Velde, C.J.H.; et al. Long-term Outcomes of Clinical Complete Responders after Neoadjuvant Treatment for Rectal Cancer in the International Watch & Wait Database (IWWD): An International Multicentre Registry Study. Lancet 2018, 391, 2537–2545. [CrossRef]

37. Coraglio, M.F.; Eleta, M.A.; Kujaruk, M.R.; Oviedo, J.H.; Roca, E.L.; Masciangioli, G.A.; Mendez, G.; Iseas, I.S. Analysis of Long-Term Oncological Results of Pathological Responses after Neoadjuvant Treatment in Locally Advanced Rectal Cancer. World J. Surg. Oncol. 2020, 18, 313. [CrossRef]

38. Jimenez-Fonseca, P.; Salazar, R.; Valenti, V.; Msaouel, P.; Carmona-Bayonas, A. Is Short-Course Radiotherapy and Total Neoadjuvant Therapy the New Standard of Care in Locally Advanced Rectal Cancer? A Sensitivity Analysis of the RAPIDO Clinical Trial. Ann. Oncol. 2022. [CrossRef]

39. Marco, M.R.; Zhou, L.; Patil, S.; Marcet, J.E.; Varma, M.G.; Oommen, S.; Cataldo, P.A.; Hunt, S.R.; Kumar, A.; Herzig, D.O.; et al. Consolidation MFOLFOX6 Chemotherapy After Consolidation MFOLFOX6 Chemotherapy in Patients with Locally Advanced Rectal Cancer. Dis. Colon Rectum 2018, 61, 1146–1153. [CrossRef]

40. Liang, H.-Q.; Dong, Z.-Y.; Liu, Z.-J.; Luo, J.; Zeng, Q.; Liao, P.-Y.; Wu, D.-H. Efficacy and Safety of Consolidation Chemotherapy during the Resting Period in Patients with Local Advanced Rectal Cancer. Oncol. Lett. 2019, 17, 1655–1663. [CrossRef]

41. Thavaneswaran, S.; Kok, P.S.; Price, T. Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: A systematic review and meta-analysis. Expert Rev. Anticancer Ther. 2017, 17, 965–979. [CrossRef] [PubMed]

42. Bahadoer, R.; Dijkstra, E. Patterns of Locoregional Failure and Distant Metastases in Patients Treated for Locally Advanced Rectal Cancer in the RAPIDO Trial. Eur. J. Surg. Oncol. 2022, 48, e34. [CrossRef]

43. Song, J.H.; Lee, J.H.; Kim, S.H.; Um, J.W. Oxaliplatin-Based Adjunct Chemotherapy Rather than Fluorouracil-Based Chemotherapy in Rectal Cancer Is More Efficient to Decrease Distant Metastasis and Increase Survival after Preoperative Chemoradiotherapy and Surgery: A Meta-Analysis. Int. J. Colorectal Dis. 2022, 37, 649–656. [CrossRef] [PubMed]

44. Mari, G.M.; Maggioni, D.; Crippa, J.; Costanzi, A.T.M.; Scotti, M.A.; Giardini, V.; Garancini, M.; Cocozza, E.; Borroni, G.; Benzoni, L.; et al. Compliance to Adjuvant Chemotherapy of Patients Who Underwent Surgery for Rectal Cancer: Report from a Multi-Institutional Research Network. World J. Surg. 2019, 43, 2544–2551. [CrossRef] [PubMed]

45. Diefenhardt, M.; Ludmir, E.B.; Hofheinz, R.-D.; Ghadimi, M.; Minsky, B.D.; Rödel, C.; Fokas, E. Association of Treatment Adherence with Oncologic Outcomes for Patients with Rectal Cancer. JAMA Oncol. 2020, 6, 1416–1421. [CrossRef]

46. Wang, S.; Wen, F.; Zhang, P.; Wang, X.; Li, Q. Cost-effectiveness analysis of long-course oxaliplatin and bolus of fluorouracil based preoperative chemoradiation vs. 5 × 5 Gy radiation plus FOLFOX4 for locally advanced resectable rectal cancer. Radiat. Oncol. 2019, 14, 113. [CrossRef]

47. Conroy, T.; Bosset, J.-F.; Etienne, P.-L.; Rio, E.; François, É.; Mesguiez-Nebout, N.; Vendrelly, V.; Artignan, X.; Bouché, O.; Gargot, D.; et al. Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2021, 22, 702–715. [CrossRef]

48. Fokas, E.; Allgäuer, M.; Polat, B.; Klautek, G.; Grabenbauer, G.G.; Fietkau, R.; Kuhnt, T.; Staib, L.; Brunner, T.; Grosu, A.-L.; et al. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2019, 37, 3212–3222. [CrossRef]

49. Fokas, E.; Schlenska-Lange, A.; Polat, B.; Klautek, G.; Grabenbauer, G.G.; Fietkau, R.; Kuhnt, T.; Staib, L.; Brunner, T.; Grosu, A.-L.; et al. Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer. Lancet Oncol. 2022, 8, e215445. [CrossRef]

50. Kasi, A.; Abbasi, S.; Handa, S.; Al-Rajabi, R.; Saeed, A.; Baranda, J.; Sun, W. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer. JAMA Netw. Open 2020, 3, e2030097. [CrossRef] [PubMed]

51. ClinicalTrials.Gov. Available online: https://clinicaltrials.gov/ct2/show/NCT04246684 (accessed on 6 May 2022).